The broadest mission of these Conferences is the collective pursuit of understanding of the issues surrounding screening for lung cancer, the main subissues being early diagnosis and early intervention.
The effectiveness of such a program is a function of the quality of the organization, implementation, execution, and acceptability of each of its components. Thus, the mission includes development of guidelines and performance indicators to maximize the benefit and minimize potential harms of the regimen of screening.
Any given Conference focuses on issues that are particularly topical at the time, including updates of research on and development pertaining to the practice of screening for lung cancer and related topics. The key topic is the curability gain resulting from the consequent early diagnosis and early treatment afforded by the I-ELCAP screening regimen.
I-ELCAP also has the capacity to function as a clinical trial network that can evaluate treatment alternatives for small, early lung cancers, including assessment of new surgical and nonsurgical technologies.